Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > IL-17A > ILA-H5219

Human IL-17A / CTLA-8 Protein, premium grade

Order Now

  • Synonym
    IL-17A,Interleukin-17A,CTLA-8,IL-17
  • Source
    Human IL17A, premium grade(ILA-H5219) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (Accession # Q16552-1 ).
    Predicted N-terminus: Gly 24
    Human IL17A, premium grade (ILA-H5219), designed for preclinical stage, has the same activity and performance with GMP Human IL-17A, which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.
  • Molecular Characterization
    IL-17A Structure

    This protein carries no "tag".

    The protein has a calculated MW of 15.1 kDa. The protein migrates as 16 kDa, 17 kDa and 19 kDa under reducing (R) condition, and 27-34 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Sterility
    The sterility testing was performed by membrane filtration method.
  • Mycoplasma
    Negative.
  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
IL-17A SDS-PAGE

Human IL17A, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS
IL-17A MALS images

The purity of Human IL17A, premium grade (Cat. No. ILA-H5219) is more than 95% and the molecular weight of this protein is around 30-46 kDa verified by SEC-MALS.

Bioactivity-ELISA
 IL-17A ELISA

Immobilized Human IL17A, premium grade (Cat. No. ILA-H5219) at 0.5 μg/mL (100 μL/well) can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with a linear range of 8-125 ng/mL (QC tested).

  • Background
    Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature cynomolgus monkey IL-17A shares 96% amino acid sequence identity with human IL-17A (3, 4). IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells (2). It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F (5, 6). IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD (7, 8). Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F (7). IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection (9‑12). It induces chemokine production, neutrophil influx, and the production of antibacterial peptides (9‑11). IL-17A/F likewise induces neutrophil migration, but IL-17F does not (11). IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock (4, 13). In contrast, it can protect against the progression of colitis by limiting chronic inflammation (12). IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity (14, 15). IL-17A has been shown to exert either tumorigenic or anti-tumor effects (16, 17).
  • Clinical and Translational Updates

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $130.00

Price(USD) : $350.00

Price(USD) : $2540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:27 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message